Nirmatrelvir-Ritonavir for the Treatment of COVID-19

44 / 107 Nirmatrelvir-Ritonavir for the Treatment of COVID-19 Results of Clinical Evaluation The first study15 (Bajema et al., 2022) was conducted in the US and assessed the effectiveness of NMV-r against molnupiravir in reducing the risk of 30-day all-cause hospitalization or death in patients considered at risk with confirmed COVID-19 and records in the Veterans Health Administration database.15. [...] Limitations include that most patients were fully vaccinated and NMV-r was not available in Italy in the first half of the study period.25 The seventh study26 (Mazzitelli et al., 2023) included all patients who were consecutively referred to the outpatient clinic for early treatment of COVID-19 at the Infectious Diseases Unit of the University Hospital of Padua in Italy.26 Overall, the study was a. [...] Study limitations include the subjective assessment of some AEs (self-reported), lack of a control group of patients who received no treatment, and the inability to assess biochemical toxicity to determine the real-life safety profile of the treatments.26 The eighth study20 (Mazzotta et al., 2023 was conducted in Italy and assessed the potential decrease of viral load from day 1 to day 7 in nasoph. [...] The incidence of AEs was 2.7% in the molnupiravir group and 5.3% in the NMV-r group, and the incidence of treatment discontinuation was 2.7% in the molnupiravir group and 5.3% in the NMV-r group. [...] The group who received NMV-r had the highest percentage of vaccinated people (97%) and the group who received remdesivir had the highest percentage of smokers (31%).25 Deaths occurred in 2 patients in the remdesivir group (1.4%) and no deaths occurred in the NMV-r group.25 Hospitalization occurred in 2.5% of patients in the NMV-r group and 4.9% in the remdesivir group.